[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 932,201,216
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.48
  • Price/Sales 13.97
  • Price/Cash Flow 37.73
  • Price/Book 28.63

Options Overview Details

View History
  • Implied Volatility 34.08% (+0.12%)
  • Historical Volatility 41.05%
  • IV Percentile 29%
  • IV Rank 34.64%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 2) 22.30 (2.25%)
  • Put/Call Vol Ratio 0.98
  • Today's Volume 50,710
  • Volume Avg (30-Day) 41,894
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 336,928
  • Open Int (30-Day) 324,674
  • Expected Range 967.57 to 1,012.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.78
  • Number of Estimates 6
  • High Estimate $9.26
  • Low Estimate $7.83
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +39.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
850.51 +16.39%
on 04/29/26
997.52 -0.77%
on 05/12/26
+50.40 (+5.36%)
since 04/10/26
3-Month
850.51 +16.39%
on 04/29/26
1,067.00 -7.23%
on 02/17/26
-48.40 (-4.66%)
since 02/12/26
52-Week
623.78 +58.69%
on 08/08/25
1,133.95 -12.71%
on 01/08/26
+234.30 (+31.01%)
since 05/12/25

Most Recent Stories

More News
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after...

LLY : 989.87 (+2.37%)
Eli Lilly (LLY) Stock Trades Up, Here Is Why

Eli Lilly (LLY) Stock Trades Up, Here Is Why

LLY : 989.87 (+2.37%)
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

Through charitable support of HATCH, United Way Worldwide, United Way of Central Indiana and the Pacers Foundation, the initiative supports efforts to expand access to protein-rich food across communities...

LLY : 989.87 (+2.37%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

BPC.CN : 0.4950 (+7.61%)
PNGAF : 0.3650 (+9.02%)
NVO : 47.00 (+1.29%)
HIMS : 25.03 (-14.10%)
LLY : 989.87 (+2.37%)
PFE : 25.87 (+0.23%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance...

BPC.CN : 0.4950 (+7.61%)
PNGAF : 0.3650 (+9.02%)
NVO : 47.00 (+1.29%)
HIMS : 25.03 (-14.10%)
LLY : 989.87 (+2.37%)
PFE : 25.87 (+0.23%)
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals...

CNTA : 39.61 (+0.05%)
LLY : 989.87 (+2.37%)
NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

NYSE issues a pre-market daily advisory direct from the trading floor.

DAR : 63.46 (-0.56%)
OFRM : 16.09 (+4.75%)
LLY : 989.87 (+2.37%)
ICE : 155.81 (-1.27%)
HHS Explored Potential SSRI Restrictions Ahead of RFK Jr. Push to Reduce Antidepressant Use

U.S. health officials recently explored whether certain selective serotonin reuptake inhibitors, or SSRIs, could face restrictions as Health Secretary Robert F. Kennedy Jr. prepared a broader initiative...

LLY : 989.87 (+2.37%)
PFE : 25.87 (+0.23%)
ELV : 393.30 (+3.03%)
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
Biotech’s Next Wave May Already be in Motion

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction,...

NTHI : 5.51 (+0.18%)
NVO : 47.00 (+1.29%)
LLY : 989.87 (+2.37%)
REGN : 723.41 (+1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,027.55
2nd Resistance Point 1,012.53
1st Resistance Point 1,001.20
Last Price 989.87
1st Support Level 974.86
2nd Support Level 959.84
3rd Support Level 948.51

See More

52-Week High 1,133.95
Last Price 989.87
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.